Table 4. Univariate and multivariate linear regression associating variables with 1-month NLR.
| Characteristics | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| β | 95% CI | P | β | 95% CI | P | ||
| Age | – | – | 0.122 | NI | |||
| Male vs. female | – | – | 0.490 | NI | |||
| CCI ≥4 | – | – | 0.584 | NI | |||
| T stage | 0.880 | 0.245–1.515 | 0.007 | – | – | 0.346 | |
| N stage | – | – | 0.990 | NI | |||
| Log10GTV | 5.427 | 3.524–7.330 | <0.001 | – | – | 0.084 | |
| Prescribed dose (Gy) | – | – | 0.457 | NI | |||
| Concurrent | – | – | 0.741 | NI | |||
| Baseline count | 0.750 | 0.447–1.053 | <0.001 | 0.655 | 0.378–0.933 | <0.001 | |
| Mean heart dose | 0.001 | 0.000–0.001 | <0.001 | – | – | 0.273 | |
| Heart V5 (%) | 0.043 | 0.021–0.065 | <0.001 | – | – | 0.127 | |
| Heart V20 (%) | 0.066 | 0.035–0.097 | <0.001 | 0.150 | 0.082–0.218 | <0.001 | |
| Heart V40 (%) | 0.065 | 0.016–0.115 | 0.010 | −0.202 | −0.308–0.096 | <0.001 | |
| Mean lung dose | 0.004 | 0.001–0.006 | 0.004 | – | – | 0.602 | |
| Lung V5 (%) | 0.135 | 0.071–0.199 | <0.001 | – | – | 0.591 | |
| Lung V20 (%) | 0.181 | 0.055–0.308 | 0.005 | – | – | 0.992 | |
| Mean body dose | 0.010 | 0.007–0.013 | <0.001 | 0.008 | 0.005–0.012 | <0.001 | |
NLR, neutrophil to lymphocyte ratio; β, standardized coefficient; CI, confidence interval; NI, not included in the multivariate model; CCI, Charlson Comorbidity Index; GTV, gross tumor volume; VX, the proportion of volume receiving at least X Gy.